In this regard, a promising cancer treatment target is CD44, a transmembrane glycoprotein overexpressed in several solid tumors such as melanoma, non-Hodgkin's lymphomas, gliomas, or meningiomas, all of them also present in the eye. This evidence concerns the gene CD44 and non-Hodgkin lymphoma.